A near miss in colorectal cancer. #ASCO26: JCOG’s EPISODE-III found low-dose aspirin fell just short on DFS in unselected stage III CRC (HR 0.84, p=0.099). The +3.4% 3Y-DFS signal and RFS trend (HR 0.87) suggest the answer may live in the biomarkers. PI3K/PIK3CA analyses ongoing.
Oral daraxonrasib hit all primary and key secondary endpoints in the phase 3 RASolute 302 trial for pancreatic cancer, nearly doubling median OS (13.2 vs 6.7 mo) and cutting risk of death 60% (HR 0.40) vs chemo. A potential new standard of care. #ASCO26 https://t.co/Ck7SGNbhvO
LY4052031 shows promising activity in metastatic urothelial cancer: 33% ORR, 75% DCR and 7.4-month median DoR in EV-pretreated patients. Nectin-4 stays a key target even after EV progression, with CYP2D6 genotyping guiding tolerability. #ASCO26
Phase 3 OptiTROP-Lung05: sac-TMT + pembrolizumab is the first ADC combo to show significant PFS benefit as first-line treatment for PD-L1+ advanced NSCLC vs pembrolizumab alone. Median PFS not reached vs 5.7 mo (HR 0.35, p<0.0001), with a manageable safety profile. #ASCO26
#ASCO26
5-FU bolus, leucovorin and DPYD… what are people actually doing in practice?
We’re running a quick 1–2 min survey looking at real-world patterns across adjuvant + metastatic CRC.
Would appreciate input from both academic + community providers.
https://t.co/nLga01z3lT
We’ll share results back.